Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Empire Ballroom C/D
601 Loyola Ave
New Orleans, LA 70113
Although important unmet clinical needs in the management of patients with ovarian cancer remain, recent developments such as the approval of poly (ADP-ribose) polymerase (PARP) inhibitors have been practice-changing. New treatment options and roles for currently available PARP inhibitors create educational gaps related to the practical application of personalized strategies to care for women with ovarian cancer. Given the rapid accumulation of data and the dynamic nature of clinical practices in ovarian cancer treatment, it is imperative that practitioners be able to understand and apply the latest evidence regarding PARP inhibitor therapy in a variety of clinical settings and scenarios. This satellite symposium will help clinicians to achieve these goals through a case-based, interactive format in which leading experts in the field of ovarian cancer will present and discuss the implications of the latest data. A variety of topics will be explored, including sequencing strategies for patients with ovarian cancer, proactive measures to prevent and mitigate potential adverse effects of PARP inhibitor therapy, the impact of germline and somatic homologous recombination deficiency (HRD) testing on the guidance of treatment selection, maintenance therapy considerations, emerging clinical trial data on PARP inhibitor therapy, and many others.
This activity is supported by educational grants from AstraZeneca, Clovis Oncology, Myriad Genetics, and Tesaro.
This educational program is directed toward all attendees of the 49th SGO Annual Meeting, including medical oncologists, pathologists, radiation oncologists, and surgical oncologists. Other attendees of the annual meeting who have an interest in the treatment of ovarian cancer such as obstetricians/gynecologists, nurses, physician assistants, fellows, and residents will also be invited to participate.
Upon completion of this activity, participants will be able to:
Robert L. Coleman, MD, FACOG, FACS
Professor & Executive Director, Cancer Network Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center